Ayr Wellness Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AYRWF research report →
Range $1 – $1
Price Chart
About the company
Ayr Wellness Inc. is a vertically integrated, multi-state cannabis company that handles the cultivation, manufacturing, and retail sales of its own branded cannabis products. Their diverse product line includes items such as concentrates, edibles, and vaporizers.
- CEO
- Scott Davido
- IPO
- 2020
- Employees
- 2,440
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on AYRWF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $432.06K
- P/E
- -0.03
- PEG
- 0.00
- P/S
- 0.03
- P/B
- 0.03
- EV/EBITDA
- -3.88
- Div Yield
- 0.00%
- Gross Margin
- 38.11%
- Op Margin
- -34.72%
- Net Margin
- -77.50%
- ROE
- -74.75%
- ROIC
- -13.40%
Latest fiscal year · YoY change
- Revenue
- $463.63M+0.0%
- Gross Profit
- $176.68M-12.7%
- Op Income
- $-160,985,000
- Net Income
- $-359,309,000-31.9%
- EPS
- $-3.24+12.0%
- OCF Growth
- -64.5%
- FCF Growth
- -21.7%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.02
- RSI (14)
- 56
- Avg Volume
- 31.84K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ayr Wellness said Q4 was pressured by Florida pricing and inventory issues, but management is responding with portfolio rationalization, cost cuts, and a bigger focus on core markets and branded wholesale growth.· March 6, 2025
- Q4 sales were $114 million, flat versus the prior quarter and just under 1% lower year over year; full-year sales were $463.6 million, also flat versus 2023.
- Adjusted gross margin in Q4 was 48.7%, down about 400 bps sequentially; full-year adjusted gross margin was 51.6% versus 55% last year.
- Q4 adjusted EBITDA was $19 million and full-year adjusted EBITDA was $100 million, both below prior trends due to price compression and margin pressure.
- Management said Florida remains a core market, but Ocala indoor cultivation is a key 2025 catalyst to improve premium flower supply and product mix.
- The company signed an LOI to sell Illinois and is further consolidating Nevada and Massachusetts to cut costs and sharpen focus.
- 2025 CapEx is expected to be approximately $10 million, excluding any incremental investment in Virginia.
Q4 sales were $114 million, flat sequentially and just under 1% lower year over year. Q4 gross profit was $35.8 million, down 17% from the prior quarter and 27% from the prior year. Q4 adjusted gross margin was 48.7%, down approximately 400 basis points sequentially. Q4 loss from continuing operations was $133.9 million, including $116 million of non-cash impairment charges. Q4 adjusted EBITDA was $19 million. Cash at quarter-end was $35.5 million. For the full year, sales were $463.6 million, in line with the prior year. Full-year gross profit was $177 million, down 13% year over year. Full-year adjusted gross margin was 51.6% versus 55% in the prior year. Full-year adjusted EBITDA was $100 million. Cash flow from continuing operations was $9.6 million, versus $24.4 million last year. CapEx was $17.7 million in 2024 and is expected to be approximately $10 million in 2025. Guidance: management expects Q1 2025 revenues to be down mid-single-digits, with a modest increase in the company’s adjusted EBITDA margin. Brad Asher said cash flow from operations is expected to remain positive.
Steve Cohen framed the quarter as difficult but part of a broader effort to build a more resilient business. He said the company is streamlining leadership, reducing redundancies, and rationalizing its state footprint to focus on markets where Ayr believes it can win over the long term. His tone was cautious but determined, repeatedly emphasizing discipline, balance-sheet health, and a long-term commitment to surviving industry volatility.
Brad Asher focused on the pressure from price compression, Florida inventory disruption, and wholesale mix, while tying those issues to lower margins. He gave specific figures: Q4 sales of $114 million, gross profit of $35.8 million, adjusted gross margin of 48.7%, adjusted EBITDA of $19 million, and ending cash of $35.5 million. For the year, he cited sales of $463.6 million, gross profit of $177 million, adjusted gross margin of 51.6%, adjusted EBITDA of $100 million, operating cash flow of $9.6 million, and 2025 CapEx of about $10 million; he also noted $4 million of ERC tax credit proceeds received after year-end.
Analysts pressed on Florida, asking how adult-use disappointment and likely added competition affect margins and supply-demand dynamics. Management said Florida remains a mainstay, but acknowledged the adult-use expectation was wrong, the state has short-term supply hiccups, and Ocala is meant to improve premium flower availability and support foot traffic rather than dramatically change margins. Questions also focused on capital allocation and divestitures; management said Virginia would be incremental to the $10 million CapEx plan, and that asset sales like Illinois are part of a broader effort to concentrate on core, more rational markets and reduce operating complexity.
The positive case is that Ayr still sees demand growth in cannabis, with transaction volumes rising and Q4 retail transactions up 1% for a fourth straight quarter of growth. Management pointed to strong momentum in Ohio, where retail sales rose 41% sequentially, Pennsylvania retail rose 8%, and wholesale CPG revenue was up 20% year over year, led by Kynd, Haze, and Later Days up 126%.
The main risk is persistent margin pressure from Florida price compression, wholesale bulk selling, and competitive new store openings across several markets. The company also reported a $133.9 million Q4 loss from continuing operations, including $116 million of impairment charges, and said Q1 2025 revenue should be down mid-single-digits, showing the turnaround is still in the early stages.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.0%
- Shares Outstanding
- 116.77M
- Float Shares
- 93.46M
of shares held by institutions
3 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| American Research & Management Co. | 450 | 0 |
Our AYRWF coverage
Recent articles, reports, and earnings notes.
No research on AYRWF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AYRWF report →Looking for Marijuana Stocks? 3 Cannabis Companies to Watch in August 2026
marijuanastocks.com · Aug 25
AYR Wellness Announces Closing of Florida, New Jersey and Nevada Operations Transfer to Arboretum
globenewswire.com · Jun 2
3 Marijuana Stock Choices For Better Investing 2026
marijuanastocks.com · May 8
Marijuana Stocks: Industry Growth, Rescheduling Impact, and Outlook
marijuanastocks.com · Apr 29
Ayr Wellness (OTCMKTS:AYRWF) and Sanuwave Health (NASDAQ:SNWV) Financial Analysis
defenseworld.net · Apr 27
AYR Wellness Announces Closing of Exit Facility and Related Transactions
globenewswire.com · Apr 10
Here Are Ways Marijuana Stocks Make Better Long Term Investments
marijuanastocks.com · Apr 1
Ayr Wellness Inc. (OTCMKTS:AYRWF) Short Interest Update
defenseworld.net · Mar 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.